FCGR2A and neoplasm: Until recently, mAb therapy was viewed as a passive therapy acting rapidly and directly against tumor cells and was not classified as “biotherapy.” CDC and ADCC/ADCP exerted by cells from the innate immunity through the engagement of FcγR are considered to play an important role in the in vivo efficacy of anti-tumor antibodies both in preclinical tumor models and in treated cancer patients (47).